The size of the Vaccine Adjuvant Market in Europe is predicted to be growing at a CAGR of 10.55% from 2022 to 2027. The market size is projected to be USD 253.8 million by 2027 and USD 153.7 million by 2022. Europe is the second-largest vaccine adjuvant market globally.
A vaccine adjuvant is an agent that helps to produce more antibodies and create a longer-lasting immunity. The European vaccine market is driven by increasing patients of infectious diseases and cancer in the region. Recently, the coronavirus outbreak has helped the European vaccine adjuvant market as it is an infectious disease. Also, the developed technology of Germany and Italy is helping the addition of innovative vaccine adjuvants for the use of flu diseases. The high prevalence of HIV and Coronavirus disease is driving the growth of the European vaccine adjuvant market. The government and NGOs have funding to clinical trials for the new adjuvant vaccine discovery to boost immunity in this pandemic situation.
However, side effects and high costs of treatment associated with the vaccine adjuvants are hampering the market's growth to some extent. In addition, the advanced and recent molecular antigen technologies will need a highly competent and powerful adjuvant vaccine for immunization, which is a big challenge for the adjuvant vaccine market. As per the European authority, the adjuvant cannot get approval without vaccines, and the lack of universities due to safety is a hurdle for this market in Europe.
This research report on the European vaccine adjuvant market has been segmented and sub-segmented into the following categories:
By Route Of Administration:
By Mechanism Of Action:
Regionally, Germany and the U.K are expected to experience robust growth in the forecast period due to increasing awareness in the region.
Italy has created tremendous demand for the newly developed adjuvant vaccine due to the high number of Coronavirus patients affected in this country. The government has taken the initiative to boost patients' immunity, and Developed healthcare is the factor that helps to the growth of the vaccine adjuvants market in Italy. In addition, the high prevalence of Influenza is more in geriatric patients, and more than 10% of the aged population in Italy are factors driving the market's growth.
The German vaccine adjuvant market is expected to grow at a robust CAGR during the forecast period due to the rising geriatric population and swine flu patients. Furthermore, in 2019, the department of vaccinology and microbiology Germany developed a new development of adjuvant vaccine combination with the enhanced immune response for particular antigens and antibodies to reduce the limitation of vaccine adjuvant in the market.
UK researchers have to work on this COVID-19 pandemic to launch a new adjuvant vaccine, generating the strongest, capable, and most durable immune response to combat the SARS-COV-2 virus. The presence of prominent players in the UK to develop vaccine adjuvants helps boost the UK vaccine adjuvant market.
Currently, the high prevalence of hepatitis B, influenza, and more demands for the aluminum vaccine adjuvant in France is fuelling the market's growth.
KEY MARKET PLAYERS:
Companies playing a prominent role in the European vaccine adjuvant market profiled in this report are MPV Technologies, Avanti Polar Lipids, Novavax Inc. Brenntag Biosector, SEPPIC, Agenus, Inc., Invivogen, SPI Pharma, Inc., CSL Limited, and OZ Biosciences.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com